A Targeted Mass Spectrometric Assay for Reliable Sensitive Hepcidin Quantification

Ahmed Moghieb1, Lia Tesfay2, Song Nie1, Marina Gritsenko1, Thomas L. Fillmore1, Jon M. Jacobs1, Richard D. Smith3, Frank M. Torti3, Suzy V. Torti2, Tujin Shi1 & Charles Ansong1

Hepcidin, a cysteine-rich peptide hormone, secreted mainly by the liver, plays a central role in iron metabolism regulation. Emerging evidence suggests that disordered iron metabolism is a risk factor for various types of diseases including cancers. However, it remains challenging to apply current mass spectrometry (MS)-based hepcidin assays for precise quantification due to the low fragmentation efficiency of intact hepcidin as well as synthesis difficulties for the intact hepcidin standard. To address these issues we recently developed a reliable sensitive targeted MS assay for hepcidin quantification from clinical samples that uses fully alkylated rather than intact hepcidin as the internal standard. Limits of detection and quantification were determined to be <0.5 ng/mL and 1 ng/mL, respectively. Application of the alkylated hepcidin assay to 70 clinical plasma samples (42 non-cancerous and 28 ovarian cancer patient samples) enabled reliable detection of endogenous hepcidin from the plasma samples, as well as conditioned culture media. The hepcidin concentrations ranged from 0.0 to 95.6 ng/mL across non-cancerous and cancer plasma specimens. Interestingly, cancer patients were found to have significantly higher hepcidin concentrations compared to non-cancerous patients (mean: 20.6 ng/ml for cancer; 5.94 ng/ml for non-cancerous) (p value <0.001). Our results represent the first application of the alkylated hepcidin assay to clinical samples and demonstrate that the developed assay has better sensitivity and quantification accuracy than current MS-based hepcidin assays without the challenges in synthesis of intact hepcidin standard and accurately determining its absolute amount.

Hepcidin is a peptide hormone derived from the liver and known to regulate systemic iron hemostasis2,11. The mature bioactive form of hepcidin is a 25 amino acid residue peptide (hepcidin-25). Smaller isoforms of hepcidin have been reported in serum and urine, but their functional significance is unclear4–6. Hepcidin dysfunction is associated with several diseases, including various cancers, sepsis and chronic kidney disease2,7 where in general hepcidin concentrations are increased. Thus, there is growing interest in utilizing hepcidin measurement as a more instructive marker for iron state, as well as diagnosis and management of iron metabolism disorders. Immunoassays have traditionally been utilized to measure hepcidin in biological fluids. However, present immunoassays measure total hepcidin and do not distinguish hepcidin forms (e.g., hepcidin-20, hepcidin-22, and hepcidin-25). Mass spectrometry (MS)-based assays for hepcidin detection have been reported4,9–13. The attractiveness of MS-based assays stems from the fact that they are able to distinguish hepcidin isoforms. Literature reports of MS-based hepcidin concentrations indicate significant variations14, most likely due to the lack of transferable hepcidin gold standards. Intact hepcidin has 4-disulfide linkages15, making consistent synthesis of intact hepcidin standard with high purity challenging, and thus degrading quantitation accuracy. To our best knowledge, the only prior report utilizing the reduced form of hepcidin-25 was by Cho et al.16 who compared the ionization efficiency of reduced and nonreduced forms in a targeted mass spectrometry assay with relatively low sensitivity (LOD 1 fmol in an un-reported matrix) and who did not apply their approach to clinical samples.

Herein we describe an improved MS-based assay that addresses the challenge(s) with intact hepcidin-25 by using a fully alkylated hepcidin-25 and the first application of the alkylated hepcidin assay to clinical samples.

1Biological Science Division, Pacific Northwest National Laboratory, Richland, WA, USA. 2Departments of Molecular Biology and Biophysics, University of Connecticut, Farmington, CT, USA. 3Department of Medicine, UConn Health Center, Farmington, CT, USA. Correspondence and requests for materials should be addressed to T.S. (email: tujin.shi@pnnl.gov) or C.A. (email: charles.ansong@pnnl.gov)
The use of an alkylated hepcidin-25 standard makes both synthesis of a consistent peptide product and accurate determination of hepcidin-25 straightforward. We show that the alkylated hepcidin-25 alleviates the low fragmentation efficiency of intact hepcidin-25. Additionally, we demonstrate that assays for alkylated hepcidin-25 provide improved detection (LOD) and limit of quantification (LOQ) values in plasma compared to current MS-based assays using intact hepcidin-25 as internal standards. Finally, we demonstrate the improved assay to measure endogenous hepcidin-25 in 70 clinical plasma samples (42 non-cancerous and 28 ovarian cancer patient samples) as well as in conditioned culture media.

Experimental Procedures
Reagents. Urea, iodoacetamide (IAA), and trichloroacetic acid (TCA) were purchased from Sigma (St. Louis, MO). Tris(2-carboxyethyl) phosphine (TCEP) was purchased from Thermo Scientific (San Jose, CA). Mass spectrometry grade solvent components, including water (H2O), formic acid (FA), and acetonitrile (ACN) were purchased from Sigma (St. Louis, MO).

Hepcidin-25 standards. The synthetic fully alkylated hepcidin-25 peptide (DTHFPICIFGGCCCH RSKCGMCCKT) labeled with 13C/15N on C-terminal lysine residue (K24), 3259.97 g/mol and unlabeled, 3251.26 g/mol were purchased from New England Peptides (Gardner, MA). The alkylated light peptide for hepcidin-25 were estimated to be of >95% purity by HPLC and the purity of crude alkylated heavy hepcidin-25 was not known.

Sample preparation. All plasma samples (including 70 patient plasma) were subjected to preparation workflow for precise detection and quantification of hepcidin-25 as shown in Supplementary Fig. 1. First, samples were thawed in ice and then vortex mixed. In a 1.5 mL LoBind tube, 100 µl plasma proteins were mixed with 10 µl heavy internal standard (71.03 ng/ml), and then denatured with 8 M urea and reduced with 10 mM TCEP for 2 h at 37°C. Protein cysteine residues were alkylated with 40 mM iodoacetamide for 2 h at room temperature in the dark. 4% of trichloroacetic acid (TCA) solution (1:1 ratio) was added. Samples were then vortexed for a few seconds and centrifuged at 18,000 × g for 5 minutes to obtain a clear supernatant. The supernatant was transferred into a new LoBind tube, then diluted with 0.1% formic acid in water for solid phase extraction (SPE) cleaning using a 1 µl SPE C18 column (Phenomenex, Torrence, CA). After SPE cleaning, the samples were completely dried in a vacuum concentrator, resuspended with 40 µl 0.1% formic acid in water and then centrifuged at 18,000 × g for 3 h at 4°C. The supernatant was transferred into liquid chromatography (LC) vials (Waters) for mass spectrometry (MS) analysis. For media, in 15 ml tube, 2 ml media was mixed with 10 µl internal hepcidin-25 standard solution (71.03 ng/ml), using the same protocol as described above for plasma samples with only one extra step of bovine serum albumin (BSA) blocking of SPE C18 columns prior to media sample cleaning.

Generation of calibration curve. Control plasma with negligible endogenous hepcidin-25 was used as the matrix for generating calibration curve. Lyophilized high-purity light alkylated hepcidin-25 peptide was reconstituted with H2O/ACN (70:30, v/v), then hepcidin-25 stock solutions (16.26, 162.56 and 1625.63 ng/ml) were diluted with the same solvent. Light alkylated hepcidin-25 was spiked into the control plasma with the final concentrations of 0, 0.5, 1, 2.5, 5, 10, 25, 50, 100 and 250 ng/ml. Heavy alkylated synthetic peptide was also spiked into each sample at a final concentration of 71.03 ng/ml. The spiked-in samples were processed according to the sample preparation described above. The generated calibration curve was used for calculating the endogenous hepcidin-25 concentrations in clinical samples, alkylated heavy synthetic peptide, and for determining the LOD and LOQ values.

Human plasma specimens. The use of human blood plasma samples was approved by the Institutional Review Boards of the University of Connecticut and Pacific Northwest National Laboratory in accordance with federal regulations. Clinical plasma samples were collected from the biorepository of UCHC with informed consent for the use of samples in research (IRB IE-08-310-1). The control (non-cancerous) and the cancer plasma specimens were obtained from healthy people with no cancer diagnosis and female diagnosed with ovarian cancer, respectively.

Media samples. HepG2 cells were obtained from American Type Culture Collection (ATCC) and cultured in Eagle’s Minimum Essential Medium (EMEM medium) from ATCC containing 10% Fetal Bovine Serum (FBS) purchased from Gemini Bioproducts. Induction of hepcidin was measured in sub-confluent cultures following replacement of the medium for 48 hours with serum-free EMEM or serum-free EMEM containing 10 ng/ml Bone Morphogenetic Protein 6 (BMP6) (R&D Systems).

Enzyme-linked immunosorbent assay (ELISA) analysis for secreted Hepcidin. Hepcidin was measured in conditioned medium from HepG2 cells using an ELISA kit from Bachem according to the manufacturer’s protocol.

Liquid chromatography (LC) separation. All samples were analyzed using a nanoACQUITY UPLC system (Waters Corporation, Milford, MA) coupled online to a TSQ Vantage triple quadrupole mass spectrometer (Thermo Scientific, San Jose, CA). Solvents used were 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in 90% acetonitrile (mobile phase B). Peptide separations were performed at a mobile phase flow rate of 400 nL/min using an ACQUITY UPLC BEH 1.7 µm C18 column (100 µm i.d. × 10 cm), which was connected to a chemically etched 20 µm i.d. fused-silica emitter via a Valco stainless steel union. 0.5 µl sample was injected.
for LC-SRM using a binary gradient of 5–20% B in 35 min, 20–25% B in 10 min, 25–38% B in 8 min, 38–95% B in 1 min, and 95% B for 6 min for a total of 75 min.

**Selected reaction monitoring (SRM) assay configuration.** Mass spectrometric detection was performed using TSQ Vantage triple quadrupole mass spectrometer (Thermo Scientific). The TSQ Vantage was operated in the same manner as previously described\(^\text{17}\). Scan width of 0.002 m/z and a dwell time of 75 ms were set for all SRM transitions. The synthesized fully alkylated hepcidin-25 peptides were further evaluated for peptide response and fragmentation pattern. Optimal collision energy (CE) values were achieved by direct infusion of the individual peptides with CE ramping as depicted in Table 1. Precursor ions monitored were 651.3 m/z (z = 5) for the endogenous hepcidin-25 and 652.8 m/z (z = 5) for the heavy standard. The relative intensity ratios among the four final selected transitions for the SRM assay were predefined by internal standard heavy peptides. Matrix interference for a given transition that fell into the mass width of Q1 and Q3 from co-eluting peptides was determined by deviation from the expected relative intensity ratios between the transitions. While four transitions were monitored, the best two transitions with no matrix interference were used to generate calibration curve and hepcidin-25 quantification in media and clinical plasma samples (Table 1).

**Data analysis.** SRM data acquired on the TSQ Vantage were analyzed using Xcalibur 2.0.7 (Thermo Scientific). Peak detection and integration were determined based on two criteria: (1) same retention time; (2) approximately same relative SRM peak intensity ratios across multiple transitions between light peptide and heavy peptide standard. All data were manually inspected to ensure correct peak detection and accurate integration. Signal to noise ratio (S/N) was calculated by the peak apex intensity over the highest background noise in a retention time region of ±15 s for the target peptides. The background noise levels were conservatively estimated by visually inspecting chromatographic peak regions. The limit of detection (LOD) and limit of quantification (LOQ) were defined as the lowest concentration point at which the S/N of surrogate peptide was at least 3 and 10, respectively. For conservatively determining the LOQ values, in addition to the requirements of the S/N to equal or be above 10, two other criteria were applied: the coefficient of variation (CV) at the concentration point be less than 20%; surrogate peptide response over the protein concentration be within the linear dynamic range. The light to heavy (L/H) SRM peak area ratio was used to generate the calibration curve and assess reproducibility. Microsoft Excel 2010 was used for statistical analysis and calibration curve plotting. The RAW data from TSQ Vantage were loaded into Skyline software\(^\text{20}\) to create high resolution figures of extracted ion chromatograms (XIC) of multiple transitions monitored for hepcidin-25.

**Results and Discussion**

**Alkylated hepcidin assay configuration.** This work used the active hormone form of hepcidin to quantify hepcidin-25; DTHFPI[CFCCG]CHRKGCGMCCKT. The mass spectrum for the intact (i.e. unalkylated) heavy form of hepcidin-25 is shown in Fig. 1. Figure 1A shows representative MS1 spectra for the intact (i.e. unalkylated) heavy hepcidin-25 and Fig. 1B shows representative MS2 spectra for dissociation of the intact heavy hepcidin-25. The MS2 spectra for the intact heavy hepcidin-25 is characterized by poor fragmentation as previously observed\(^\text{19}\). This is likely due to the four disulfide linkages which also makes synthesis of a consistent peptide product challenging\(^\text{20,21}\), and in part accounting for the significant variability reported for MS-based assays\(^\text{14}\). Thus, we reasoned that elimination of disulfide linkages via generation of an alkylated hepcidin-25 peptide product may significantly contribute to reducing the challenge associated with synthesis while simultaneously improving the low fragmentation efficiency associated with the disulfide linkages in intact hepcidin. Figure 1C,D show representative MS1 and MS2 spectra for the alkylated heavy form of hepcidin-25 respectively. Noticeably, the alkylated heavy form of hepcidin-25 provided a much higher fragmentation efficiency with a rich MS2 spectra (Fig. 1D) compared to the intact (i.e. unalkylated) heavy form of hepcidin-25 (Fig. 1B), which is consistent with our hypothesis. The list of fragment ions (b & y ions) for intact and alkylated heavy Hecpcidin-25 are shown in Supplementary Table 4.

| Compound name | Precursor ion** | Product ion | Collision energy | Fragment |
|---------------|----------------|-------------|------------------|----------|
| DTHFPI[CFCCG]CHRKGCGMCCKT, M 3251.259 | 651.259 | 501.209 | 22 | [b4]⁺ |
| DTHFPI[CFCCG]CHRKGCGMCCKT, M 3259.971 | 652.862 | 501.209 | 22 | [b4]⁺ |

Table 1. The optimal collision energies (CEs) and selected transitions for alkylated hepcidin-25 (light and heavy versions). C = C[+57.0], K = K[13C6,N2], Ions chosen as qualifiers.
Calibration curve for hepcidin-25 quantification. High-purity alkylated light hepcidin with a concentration range from 0.5–250 ng/mL was spiked into the control plasma with negligible endogenous hepcidin, with a fixed concentration (71.03 ng/mL) for alkylated heavy hepcidin.

**Calibration curve for hepcidin-25 quantification in plasma.** To evaluate the hepcidin-25 assay performance a calibration curve was generated. High-purity alkylated light hepcidin-25 was spiked into non-cancerous human plasma with negligible endogenous hepcidin-25. We note that all clinical samples are treated with IAA to convert hepcidin to the analyzed alkylated hepcidin. The linearity was assessed by a 10-point calibration curve with concentrations ranging from 0.5 to 250 ng/mL (Supplementary Table 1). Figure 2 shows that the calibration curve has excellent linearity with a coefficient of correlation $R^2 \sim 0.99$. Across the concentration range of the calibration
curve, a median coefficient of variation (CV) of 2.66% was obtained with CV at 7.73% for the lowest concentration point (0.5 ng/mL) and at 2.36% for the highest concentration point (250 ng/mL) (Supplementary Table 1).

The calibration curve generated was leveraged to determine the LOQ and LOD for the hepcidin-25 assay developed when combined with the S/N ratio at each concentration point (Supplementary Table 1). Figure 3 depicts extracted ion chromatograms (XICs) of transitions monitored for alkylated endogenous and heavy hepcidin-25 at various concentrations. The LOD for the current assay was determined to be <0.5 ng/ml, and the LOQ was assessed to be 1 ng/ml. The LOD and LOQ values are better than what has been previously reported using intact hepcidin as an internal standard. For example, Delaby et al.14 recently reported a mass spectrometry-based hepcidin-25 assay with analytical validation performed according to ISO15189 norms. In that study they reported LOD of 2 ng/mL and LOQ of 6 ng/mL in serum. It is likely that the improved LOD and LOQ stem from the improved sensitivity offered by the higher fragmentation efficiency of the alkylated hepcidin when compared to the intact hepcidin bearing disulfide linkages.

Endogenous hepcidin-25 quantification in human plasma. Next, we applied our developed LC-SRM assay to quantify hepcidin concentration in human plasma specimens. Endogenous hepcidin-25 was measured in 70 clinical plasma samples (42 non-cancerous and 28 ovarian cancer patient samples). We note that all clinical samples are treated with IAA to convert hepcidin to the analyzed alkylated hepcidin. With the established calibration curve and the measured L/H peak area ratio for individual samples, the hepcidin-25 concentration in each sample could be calculated and expressed as ng/mL in plasma. The measured hepcidin-25 concentration ranged from 0 ng/mL to 95.57 ng/mL across non-cancerous and cancer samples. The measured hepcidin-25 concentrations are shown in Supplementary Table 1 and Fig. 4, they are largely within the range of our calibration curve. A prior study14 using a similar analytical approach to measure hepcidin-25 in serum indicated quantitation of hepcidin-25 in cohort samples did not exceed 140 ng/mL. That observation is largely consistent with the present study data where the highest hepcidin concentration reported in plasma was 95.6 ng/mL, in part supporting the validity of the assay developed using alkylated hepcidin-25 instead of traditional intact hepcidin-25.

Prior studies have suggested that hepcidin-25 serum levels may serve as a predictive biomarker in renal cell carcinoma and non-small cell lung cancer22,23. We also assessed the potential for hepcidin to discriminate between non-cancerous plasma and ovarian cancer patient plasma sample types. Non-cancerous plasma sample concentrations (n = 42) ranged between 0 ng/mL and 26.7 ng/mL with a median value of 4.28 ng/mL (a mean value of 5.9 ng/mL) (Supplementary Table 2). Ovarian cancer patient plasma concentrations (n = 28) ranged between 0.12 ng/mL and 95.6 ng/mL with a median value of 15.18 ng/mL (a mean value of 20.6 ng/mL). The increased hepcidin-25 amounts in serum of ovarian cancer patients relative to non-cancerous was statistically significant (p < 0.001) (Supplementary Table 2). Interestingly, this observation was consistent with prior reports of increased serum hepcidin-25 levels in renal cell carcinoma and non-small cell lung cancer22,23. Definitely, large clinical cohort studies are needed for the validation of hepcidin as a useful cancer biomarker.
Quantification of hepcidin-25 concentration in spent media. While the measurement of hepcidin in biological fluids (e.g., urine and plasma) is important in the context of the diagnosis and management of diseases in which iron metabolism is affected, the ability to measure hepcidin-25 in *in vitro* systems (e.g., cell culture) is also equally important to dissect and understand mechanisms underlying diseases in which iron metabolism is affected to identify novel therapies. Hepcidin in the context of cell culture is primarily partitioned into the

**Figure 4.** Application of developed hepcidin assay for quantification of endogenous hepcidin in clinical plasma samples. Cancer patients were found to have significantly higher hepcidin concentration than non-cancerous patients ($p < 0.001$).

**Figure 5.** XICs of transitions monitored for alkylated endogenous and heavy hepcidin in hepatocytes cell media (HepG2) in the presence (A) and absence of BMP6 (10 ng/ml) (B). The black arrows indicated the location of SRM peak apex based on the retention time of heavy internal standard. Transition legend at bottom left hand of figure defines the blue and purple XIC traces for $y_{18}$ and $y_{17}$, respectively. (C) L/H hepcidin ratios for both HepG2 control and with BMP6 obtained from triplicate analysis with the standard error of mean. (D) Secretion of hepcidin in conditioned media. Secreted hepcidin in conditioned media was measured using ELISA. Hepcidin quantity was normalized to $1 \times 10^6$ cells.
condition media as opposed to being retained intracellularly. Therefore, we also developed an analytical approach for quantification of hepcidin-25 in spent media from mammalian cell culture systems. Specifically, we examined hepcidin-25 quantification in spent media from the hepatoma cell line HepG2. Because several studies have shown that bone morphogenetic proteins (BMPs) including BMP 2, 4, 6, and 9 stimulate hepcidin expression24–26, we also examined hepcidin-25 quantification in spent media from the hepatoma cell line HepG2 treated with BMP 6. Representative XICs of transitions monitored for alkylated endogenous and heavy hepcidin-25 in media from control and BMP 6-treated HepG2 cells are shown in Fig. 5A,B. As expected, BMP6 increased the abundance of hepcidin in conditioned media from HepG2 cells compared to untreated cells (Fig. 5C). Triplet analysis showed an increase in hepcidin-25 after BMP6 stimulation (Fig. 5C and Supplementary Table 3). This was consistent with observations from immunoassay (ELISA) measurement of hepcidin under the same conditions (Fig. 5D). Thus, ELISA assay provides an orthogonal validation of hepcidin SRM assay.

**Conclusion**

Hepcidin is a cysteine-rich tightly folded 25-residue peptide hormone containing four disulfide bonds, making endogenous hepcidin both challenging to synthesize20,21 and hampering reliable detection. Here we have developed a simple reliable targeted LC-SRM assay for quantification of hepcidin-25 in complex biological matrices by replacement of intact (disulfide linked) hepcidin standard with fully alkylated hepcidin standard. Our approach overcomes: (i) the challenges in synthesis and cost of generating intact hepcidin peptide, and (ii) the low fragmentation efficiency that characterizes the intact hepcidin peptide which challenges quantification accuracy. The new assay provided reliable detection of endogenous hepcidin-25 in human plasma samples and conditioned cell culture media. Additionally, our study suggests the potential for hepcidin to discriminate between non-cancerous plasma and plasma from patients with ovarian cancer. Larger cohort studies are definitely required to further validate hepcidin as a potential biomarker for ovarian cancer. In summary, we anticipate our newly developed assay will facilitate more reliable, sensitive, and low-cost quantification of hepcidin in complex biological samples.

**Data Availability**

All the Skyline-processed SRM results reported in this study can be accessed at Panoram (Access link: https://panoramaweb.org/lxv9u); the reviewer account: Email: panorama + pnnl5@proteinsms.net, Password: WSVbZ2&R).

**References**

1. De Domenico, I. et al. The Molecular Mechanism of Hepcidin-mediated Ferroportin Down-Regulation. *Mol. Biol. Cell* **18**, 2569–2578 (2007).
2. Andrews, N. C. Forging a field: The golden age of iron biology. *Clin. Chem.* **53**, 1557–1567 (2015).
3. Moe, M. K., Hardang, I. M. & Hagve, T. A. Novel circulating isoforms of hepcidin. *Ther. Biol. Chem.* **276**, 7806–7810 (2003).
4. Girelli, D., Nemeth, E. & Swinkels, D. W. Hepcidin in the diagnosis of iron disorders. *Blood* **120**, 2809–2813 (2016).
5. Kali, A., Charles, M. V. & Seetharam, R. S. Hepcidin - A novel biomarker with changing trends. *Clin. Chem. Lab. Med.* **51**, 171–180 (2009).
6. Park, C. H., Valore, E. V., Waring, A. J. & Ganz, T. Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. *J. Biol. Chem.* **276**, 7806–7810 (2001).
7. Girgili, S., Demir, E., Goksin, E. & Dogan, K. E. Increased serum hepcidin-25 level and increased tumor expression of hepcidin in renal cell carcinoma. *J. Urol.* **2009**, 10289–10293 (2006).
8. Kali, A., Charles, M. V. & Seetharam, R. S. Hepcidin - A novel biomarker with changing trends. *J. Pharmacol. Toxicol. Methods* **51**, 171–180 (2009).
9. Li, H. **et al.** Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. *J. Pharm. Pharmacol.* **61**, 35–40 (2015).
10. Lefebvre, T. **et al.** LC-MS/MS method for hepcidin-25 measurement in human and mouse serum: Clinical and research implications in iron disorders. *Clin. Chem. Lab. Med.* **53**, 1557–1567 (2015).
11. Murphy, A. T., Witcher, D. R., Luan, P. & Wroblewski, V. J. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. *Blood* **110**, 1048–1054 (2007).
12. Li, S., Nakayama, T., Akinc, A., Wu, S. L. & Karger, B. L. Development of LC-MS methods for quantification of hepcidin and demonstration of siRNA-mediated hepcidin suppression in serum. *J. Proteome Res.* **6**, 110–119 (2015).
13. Swensen, A. C. **et al.** Whole blood and urine bioactive Hepcidin-25 determination using liquid chromatography mass spectrometry. *Anal. Biochem.* **517**, 23–30 (2017).
14. Delaby, C. **et al.** Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job? *EutA Open Proteomics* **3**, 60–67 (2014).
15. Krause, A. **et al.** LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett.* **480**, 147–150 (2000).
16. Cho, K.-C. **et al.** SRM-MS Method Development for Hepcidin-25 Peptide. *J. Anal. Methods Chem.* **2018**, Article ID 9653747 (2018).
17. Shi, T. **et al.** Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. *Proc. Natl. Acad. Sci. USA* **109**, 15395–15400 (2012).
18. MacLean, B. **et al.** Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. *Bioinformatics* **26**, 966–968 (2010).
19. Hwang, S. I. **et al.** Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method. *Clin. Chim. Acta* **412**, 2241–2247 (2011).
20. Chua, K. **et al.** Small cyclic agonists of iron regulatory hormone hepcidin. *Bioorganic Med. Chem. Lett.* **25**, 4961–4969 (2015).
21. Jordan, J. B. **et al.** Hepcidin revisited, disulfide connectivity, dynamics, and structure. *J. Biol. Chem.* **284**, 24155–24167 (2009).
22. Kamai, T., Tomosugi, N., Abe, H., Arai, K. & Yoshida, K. I. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. *BMC Cancer* **9**, 270 (2009).
23. Chen, Q. **et al.** Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage. *Thorac. Cancer* **5**, 14–24 (2014).
24. Shannumg, N. K. N. & Cherayil, B. J. Serum-induced up-regulation of hepcidin expression involves the bone morphogenetic protein signaling pathway. *Biochem. Biophys. Res. Commun.* **411**, 383–386 (2013).
25. Andriopoulos, B. **et al.** BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. *Nat. Genet.* **41**, 482–487 (2009).
26. Truksa, J., Peng, H., Lee, P. & Beutler, E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. *Proc. Natl. Acad. Sci. USA* **103**, 10289–10293 (2006).
Acknowledgements
This work was supported in part by NCI R01CA188025 (SVT), NCI R01CA171101 (FMT) and P41 GM103493 (R.D.S.). The experimental work described herein was performed in the Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, a national scientific user facility sponsored by the United States of America Department of Energy under Contract DE-AC05-76RL01830.

Author Contributions
Designed experiment: Suzy V. Torti, Tujin Shi and Charles Ansong. Performed experiments: Ahmed Moghieb, Lia Tesfay, Song Nie, Marina Gritsenko, Thomas L. Fillmore, Jon M. Jacobs. Contributed to manuscript writing and editing: Ahmed Moghieb, Richard D. Smith, Frank M. Torti, Suzy V. Torti, Tujin Shi and Charles Ansong.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-43756-9.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019